secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001819790-25-000100
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus annual meeting: directors elected, say-on-pay approved, Ernst & Young ratified
--------------------------------------------------------------------------------

- Stockholders elected Bobak Azamian, M.D., Ph.D. (20.8M for) and Katherine Goodrich, M.D. (26.8M for) as Class II directors.
- Non-binding advisory vote approved named executive officer compensation: 27.1M for, 416,845 against, 16,635 abstain.
- Stockholders selected an every-1-year frequency for future say-on-pay votes (26.9M votes for 1 year).
- Ratification of Ernst & Young LLP as independent auditor for FY2025 approved: 34.7M for, 125,755 against, 7,803 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000100/0001819790-25-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000100/tars-20250612.htm
  HTML page:      https://secwatch.observer/filing/0001819790-25-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer